eng Oriental Scientific Publishing Company Biosciences Biotechnology Research Asia 0973-1245 2023-06-30 20 2 465 475 10.13005/bbra/3102 46364 article Shertate Yash 1 Kamble Sarika 2 Borse Laxmikant 2 Department of Quality Assurance Sandip Foundation’s Sandip Institute of Pharmaceutical Science,Affiliated to Savitribai Phule Pune University, Mahiravani, Nashik, Maharashtra 422213, India Department of Pharmacology Sandip Foundation’s Sandip Institute of Pharmaceutical Science, Affiliated to Savitribai Phule Pune University, Mahiravani, Nashik, Maharashtra 422213, India Combination of all the aspects are covered in this review from anti-influenza drug.Several articles neglected to include a point of view. The majority of review papers emphasiseon epidemiology. In order to lessen the financial burden of disease and its negative effects, it is important to raise awareness about disease and how to manage it.The medicine favipiravir,additionally called T-705 (5-fluro-2-oxo-1H-pyrazine-3-carboxamide), by selection and powerfully inhibits the polymer-dependent polymer accelerator (RdRp) of polymer viruses. Favipiravir was discovred by the company Toyama Chemical Co., Ltd.By searching a chemical library for the respiratory illness virus's antiviral properties. Favipiravir-RTP (favipiravir ribofuranosyl-5′-triphosphate), the active version of the drug, is recognised by RdRpas a substrate and restrains the polymer accelerator's activityFavipiravir is efficient against a broad kind of subtypes and variations of respiratory disorder viruses. https://www.biotech-asia.org/vol20no2/favipiravir-an-effective-rna-polymerase-modulating-anti-influenza-drug/ Antiviral Activity; Favipiravir; Polymer Dependent Polymer Acecelerator(RdRp); Respiratory disorder viruses